Accreditation: 12.75 Nursing Contact Hours | 12.75 ABIM MOC II | 12.75 AMA PRA Category 1 Credit™ | 12.75 ACPE Pharmacy
Venue: Bell Harbor International Conference Center , 2211 Alaskan Way, Seattle, WA, 98121, United States
Official conference page for 2026 Seattle Cellular Therapy Summit. https://binaytara.org/projects/conferences/2026-seattle-cellular-therapy-summit
Day 1: Friday, August 14th, 2026
All timings are in Pacific Time (PDT, GMT-07:00) time.
Session Chair: Lawrence Fong, MD
09:45 AM - 10:00 AM
Immuno-oncology for GU Malignancies – Lawrence Fong, MD
10:00 AM - 10:15 AM
Lung Cancer: Tarlatamab – Sid Devarakonda, MD
10:15 AM - 10:30 AM
Malignant Melanoma: Lifileucel and Beyond – Max Julve, MD
10:30 AM - 10:45 AM
Immunotherapy for Sarcoma – Lara E. Davis, MD
10:45 AM - 11:15 AM
Panel Discussion
Moderators:
Lawrence Fong, MD
Panelists:
Sid Devarakonda, MD; Max Julve, MD; Lara E. Davis, MD
Session Chair: Folashade Otegbeye, MPH, MBChB
11:15 AM - 11:30 AM
Novel FOLR1 CAR-T Therapy – Soheil Meshinchi, MD, PhD
11:30 AM - 11:45 AM
FACT Standards for Immune Effector Cells in the Community Setting – Folashade Otegbeye, MPH, MBChB
11:45 AM - 12:15 PM
Panel Discussion
Moderators:
Folashade Otegbeye, MPH, MBChB
Panelists:
Soheil Meshinchi, MD, PhD
Session Chair: Natalie Wuliji, DO
01:15 PM - 01:30 PM
Multispecific CAR-T — Will They Change Our Standard of Care? – Saurabh Dahiya, MD
01:30 PM - 01:45 PM
In-Vivo CAR-T Platforms – Hans-Peter Kiem, MD, PhD
01:45 PM - 02:00 PM
CAR-T Therapy for Autoimmune Disorders – Natalie Wuliji, DO
02:00 PM - 02:30 PM
Panel Discussion
Moderators:
Natalie Wuliji, DO
Panelists:
Saurabh Dahiya, MD; Hans-Peter Kiem, MD, PhD
Session Chair: Filippo Milano, MD, PhD
02:45 PM - 03:00 PM
Immunotherapy for Myeloid Malignancies — Challenges and Promises – Hany Elmariah, MD, MS
03:00 PM - 03:15 PM
Cellular Therapy in Allogeneic Transplant (Orca-T, Omidubicel and Beyond) – Filippo Milano, MD, PhD
03:15 PM - 03:30 PM
ALL — Focus on Immunotherapeutic Approaches, Approved and Investigational Options – Ryan Cassaday, MD
03:30 PM - 03:45 PM
Panel Discussion
Moderators:
Filippo Milano, MD, PhD
Panelists:
Hany Elmariah, MD, MS; Ryan Cassaday, MD
Session Chair: Alexey Danilov, MD, PhD
03:45 PM - 04:00 PM
Immunotherapy (CAR-T and Bispecific Antibodies) for CLL – Jennifer Huang, MD, PhD
04:00 PM - 04:15 PM
How Will CLL Be Treated in 2030? – Alexey Danilov, MD, PhD
04:15 PM - 04:45 PM
Panel Discussion
Moderators:
Alexey Danilov, MD, PhD
Panelists:
Jennifer Huang, MD, PhD
Day 2: Saturday, August 15th, 2026
Session Chair: Mazyar Shadman, MD, MPH
08:00 AM - 08:15 AM
Barriers to CAR-T Use — Challenges and Opportunities – Mazyar Shadman, MD, MPH
08:15 AM - 08:30 AM
Bispecific Antibodies in Community Setting — General Principles – Sibel Blau, MD
08:30 AM - 08:45 AM
Next-Generation T-Cell Engagers – Krish Patel, MD
08:45 AM - 09:00 AM
State of Cellular Immunotherapy in 2030 – Matthew Alexander Lunning, DO
09:00 AM - 09:30 AM
Panel Discussion
Moderators:
Mazyar Shadman, MD, MPH
Panelists:
Sibel Blau, MD; Krish Patel, MD; Matthew Alexander Lunning, DO
Session Chair: Krish Patel, MD
09:30 AM - 09:45 AM
Current Role of Immunotherapy in Treatment of DLBCL – Nilanjan Ghosh, MD, PhD
09:45 AM - 10:00 AM
How Will DLBCL Be Treated in 2030? – Sonali Smith, MD
10:00 AM - 10:30 AM
Panel Discussion
Moderators:
Krish Patel, MD
Panelists:
Nilanjan Ghosh, MD, PhD; Sonali Smith, MD
This activity is supported with an Independent Medical Education grant from Amgen.
